No Data
No Data
Reviva Pharmaceuticals Reports Q3 EPS (25c), Consensus (25c)
Reviva Pharmaceuticals Reports Progress on Brilaroxazine Trials and Financial Results for Q3 2024
Reviva Pharm Holdings 3Q Loss/Shr 25c >RVPH
Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital
Reviva Pharm Holdings Price Target Maintained With a $15.00/Share by D. Boral Capital
Press Release: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
No Data
No Data